Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma

BJU International

Volumn 102, Issue 5, 2008, Pages 566-571

  Li, Liao Yuan ^a   Yang, Ming ^a   Zhang, Hai Bin ^a   Su, Xi Kang ^a   Xu, Wen Feng ^a   Chen, Yong ^a   Shen, Zhou Jun ^b   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bladder; Fibronectin; Residual tumour; Transitional cell carcinoma; Transurethral resection

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; FIBRONECTIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; POLYSTYRENE; TUMOR MARKER;

ADULT; AGED; ANALYZER; ARTICLE; AUTOANALYSIS; BLADDER CARCINOMA; CANCER GRADING; CHEMOLUMINESCENCE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CREATININE; CYSTECTOMY; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 48749105449     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07637.x     Document Type: Article

References (31)

1. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992 19 : 429 33
2. Andius P, Holmang S. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004 93 : 980 4
3. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumours: relationship to grade, immunohistochemical expression of tumour markers, mitotic frequency and DNA ploidy. J Urol 2001 165 : 1124 30
4. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995 153 : 1823 7
5. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000 163 : 73 8
6. Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int 2004 94 : 18 21
7. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002 167 : 1634 7
8. Smith JA Jr., Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and Tis). The American Urological Association. J Urol 1999 162 : 1697 701
9. Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004 72 : 99 102
10. Mersdorf A, Brauers A, Wolf JM, Schneider V, Jakse G. Second TUR for superficial bladder cancer: a must? J Urol 1998 159 (Suppl. A542
11. Klän R, Loy V, Huland H. Residual tumour discovered in routine second TUR in patients with T1 transitional cell carcinoma of the bladder. J Urol 1991 146 : 316 8
12. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 1999 162 : 74 6
13. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006 97 : 1199 201
14. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006 97 : 1194 8
15. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001 165 : 808 10
16. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998 16 : 17 22
17. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumours. J Urol 2002 168 : 465 9
18. Lokeshwar VB, Soloway MS. Current bladder tumour tests: does their projected utility fulfill clinical necessity? J Urol 2001 165 : 1067 77
19. Lorenzo Gomez MF, Schroeder G. The role of tumour markers in prognosing transitional bladder cancer. Actas Urol Esp 2003 27 : 501 12
20. Redwood SM, Liu BC, Weiss RE, Hodge DE, Droller MJ. Abrogation of the invasion of human bladder tumour cells by using protease inhibitor(s). Cancer 1992 69 : 1212 9
21. Katayama M, Hino F, Odate Y et al. Isolation and characterization of two monoclonal antibodies that recognize remote epitopes on the cell-binding domain of human fibronectin. Exp Cell Res 1989 185 : 229 36
22. Malmstrom PU, Larsson A, Johansson S. Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer. Br J Urol 1993 72 : 307 10
23. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Evaluation of two new urinary tumour markers: bladder tumour fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 2000 6 : 3585 94
24. Mutlu N, Turkeri L, Emerk K. Analytical and clinical evaluation of a new urinary tumour marker: bladder tumour fibronectin in diagnosis and follow-up of bladder cancer. Clin Chem Lab Med 2003 41 : 1069 74
25. Menendez V, Fernandez-Suarez A, Galan JA, Perez M, Garcia-Lopez F. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology 2005 65 : 284 9
26. Sobin LH, Wittekind CH. Urinary bladder. In Sobin LH, Wittekind CH, TNM Classification of Malignant Tumours, 6th edn. New York : Wiley-Liss, 2002 : 199 202
27. Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002 168 : 475 8
28. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30
29. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004 172 : 1123 6
30. Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005 66 (Suppl. 1 90 107
31. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003 61 : 109 18